PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

NCT ID: NCT00523107

Last Updated: 2025-06-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 91 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-08-31
• Study Completion Date: 2008-04-30

Brief Summary

The objective of this study is to conduct a trial in the spirit of providing as much as possible the benefit of PG2 treatment to eligible patients and to evaluate the efficacy and safety of PG2 for relieving fatigue among advanced cancer patients who are under standard palliative care (SPC) at hospice setting and have no further curative options available. Patient's fatigue status, to be measured by the Brief Fatigue Inventory-Taiwanese Form (BFI-T), will be the primary endpoint. The fatigue improvement response rate among patients between two study arms will then be compared as the basis for efficacy evaluation at the end of the first treatment cycle, and will be the primary endpoint. Other endpoints, the fatigue improvement response rate and the mean fatigue scores change from baseline among patients within and between cycles will be included in the secondary efficacy endpoints, and will be compared between two study arms. Patients' quality of sleep, appetite, pain, fatigue, nausea, vomiting and global quality of life (QoL) will be also measured by 11 questions (SS11) from EORTC QLQ-C30 for secondary endpoint evaluation. The other secondary endpoints include Karnofsky performance scores, and weight change and its related c-reactive protein level of the patients.

• BFI-T (Brief Fatigue Inventory - Taiwan) : The BFI is a 9-item self-administered questionnaire which was developed by MD Anderson Cancer Center offers assessing levels of fatigue. Subjects rate each item based on how they felt for the preceding week using a 1-10 numeric rating scale (10 being the most unfavorable response). The single construct of the BFI allows for the mean of the nine items to be the overall score. The score is categorized as mild (1-3), moderate (4-6), and severe (7-10). The scale is a reliable instrument that correlates highly with similar fatigue and performance status measures.

Detailed Description

This is a trial to evaluate use of PG2 for fatigue improvement in advanced cancer patients who are under standard palliative care at hospice setting and have no further curative options available. Only patients who give consent to participate in this study and meet all other inclusion and exclusion criteria will be eligible to enroll into this study. All patients will continue the standard palliative care (SPC) during this study.

The main aim of this trial is to compare improvement of patient's fatigue status between patients with or without PG2 treatment. Patient's fatigue status will be assessed by the Brief Fatigue Inventory-Taiwanese (BFI-T) Form. Each patient's fatigue improvement response will be defined as an improvement in the mean fatigue scores by at least 10% from baseline. Other quality of life parameters will be measured by the 11 questions (SS11) of the EORTC QLQ-C30 and by Karnofsky performance scale. Patient's weight change and its related c-reactive protein will be followed. There are two study arms in this trial: 1) the PG2 plus SPC arm; and 2) the Placebo plus SPC arm.

Conditions

Fatigue

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

PG2

PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.

Group Type: EXPERIMENTAL

PG2

Intervention Type: DRUG

PG2 500 mg / 500 ml normal saline t.i.w. per week

Placebo

500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.

Group Type: PLACEBO_COMPARATOR

PG2

Intervention Type: DRUG

PG2 500 mg / 500 ml normal saline t.i.w. per week

Placebo

Intervention Type: DRUG

500 ml normal saline t.i.w. per week

Interventions

PG2

PG2 500 mg / 500 ml normal saline t.i.w. per week

Intervention Type: DRUG

Placebo

500 ml normal saline t.i.w. per week

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed the informed consent form
• ≧ 18 years old
• Have locally advanced or metastatic cancer or inoperable advanced cancer
• Under standard palliative care (SPC) at hospice setting and have no further curative options available
• BFI fatigue score ≧ 4
• Women with childbearing potential must use contraception
• Life expectancy of at least 3 months as determined by the investigator
• Willing and able to complete quality of life questionnaires

Exclusion Criteria

• Pregnant or breast-feeding females
• Uncontrolled systemic disease such as active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus
• Take central nervous system stimulators such as Methylphenidate within last 30 days
• In other investigational drug trials within last 30 days
• Karnofsky performance scores < 30%
• Diagnosed as dying status

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

PhytoHealth Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yuen-Liang Lai, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mackay Memorial Hospital

Locations

Mackay Memorial Hospital

New Taipei City, , Taiwan

Countries

Taiwan

Other Identifiers

PH-CP012

Identifier Type: -

Identifier Source: org_study_id